A new cancer jab has shown ‘unprecedented’ results in eradicating entire tumours, doctors have said after early stage trials.The jab, called amivantamab, brought dramatic changes within weeks for some patients, in a trial spanning 11 countries.The triple-action injection was offered to patients whose cancers had resisted normal treatment in an international study by the Institute of Cancer Research (ICR).
Some 42% of patients saw their tumours shrink, while 15 people found the drug had melted the tumours away completely. Professor Kevin Harrington, a consultant oncologist at the Royal Marsden NHS Foundation Trust, said: ‘These are unprecedentedly strong responses in patients whose disease has become resistant to both chemotherapy and immunotherapy.Sign up for all of the latest stories Start your day informed with Metro's News Updates newsletter or get Breaking News alerts the moment it happens.‘This is a group of patients for whom treatment options are extremely limited, so seeing this level of benefit is very striking.’ Amivantamab is given with an injection, whereas many other cancer treatments require intravenous drips or other invasive methods.
Scientists gave the drug to 102 people who had head and neck cancers that had spread to other parts of the body or become recurrent.Head and neck cancers affect about 12,800 people in the UK every year, and are the sixth most common form of cancer globally.The trial included patients from 55 hospitals in 11 countries whose cancer type was projected to have ‘very poor outcomes’.
Despite this, those who received amivantamab saw their tumours start to respond within about six weeks of starting the treatment.Carl Walsh, 56, from Birmingham, joined the study at The Royal Marsden in July 2025 after chemotherapy and immunotherapy were both unsuccessful for his tongue cancer.‘I now feel able to live a normal life.
Before starting the trial, I struggled to speak properly and found eating difficult because of the swelling and pain.‘Since beginning treatment, the swelling has reduced significantly, and my pain levels have improved considerably.Trending Now Satellite images show China is building nuke launch pads and bunkers World 1 day ago By Ryan Prosser Dad on holiday blocked from flying home despite living in Yorkshire for 40 years Neighbours 'heard screams and shouts' in weeks before man, woman and child fell to deaths The heartbreaking secret Wimbledon Common victim took to her grave ‘I’m also no longer experiencing the same life-impacting side effects that I had during chemotherapy.’ The injection is also faster, more convenient for patients, and ‘significantly easier’ to deliver in outpatient clinics, the ICR said.
The injection, developed by pharma giant Johnson & Johnson, is now being tested in about 60 clinical trials, mainly for lung cancer, but also for colorectal, brain and gastric cancers.Professor Kristian Helin, chief executive of the ICR, said: ‘Achieving this level of tumour response and encouraging survival outcomes in such a challenging to treat group represents a significant step forward.’ Get in touch with our news team by emailing us at [email protected] more stories like this, check our news page.
MORE: Tracy Shaw ‘has fun being me’ as she shows off new wig before chemotherapy MORE: My ‘new mum’ exhaustion turned out to be incurable cancer MORE: They gave me 6 months to live – then told me I was lucky Comments Add as preferred source News Updates Stay on top of the headlines with daily email updates.This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.Your information will be used in line with our Privacy Policy HomeNewsTech Related topics CancerNHS Record-breaking 3,000ft long bridge can withstand earthquakes and extreme weather Tech 1 day ago By Rory McKeown Inside the Met Police's £750 million tech force and its battle to use AI Tech 3 days ago By Josh Milton
Read More
